Security key
29286M113
enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW)
CUSIP: 29286M113
Q4 2023 13F Holders as of 31 Dec 2023
- Security type / class
- Equity / *W EXP 10/31/202
- Total 13F shares
- 4,440,160
- Total 13F value
- $3,691,565
- Share change
- +3,965,084
- SEC-reported price per share
- $0.85
- Number of holders
- 21
- Value change
- +$3,287,750
- Number of buys
- 20
Report period
Q4 2023
Institutions
21
Top holders
10
ENGNW full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2024
enGene Therapeutics Inc. SEC filings
enGene Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29286M113
Recent filing periods:
Ownership snapshot
Top reported holders of ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Forbion Growth Sponsor FE...
Disclosed value leader
—
Comparable rows
0/6
Latest evidence
30 Nov 2023
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
6 rows are not safely comparable across share classes.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Forbion Growth Sponsor FEAC I B.V.'s linked filing trail.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Forbion Growth Sponsor FEAC I B.V. |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
—
5,502,338 shares
mixed-class rows
|
— | 31 Oct 2023 |
| Forbion Capital Fund III Cooperatief U.A. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
2,894,735 shares
|
— | 31 Oct 2023 |
| BVF PARTNERS L P/IL |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
104,257 shares
|
— | 31 Oct 2023 |
| Jason David Hanson |
3/4/5
Chief Executive Officer, Director
|
—
class O/S missing
|
—
512,826 shares
|
— | 31 Oct 2023 |
| Richard P. Bryce |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
153,000 shares
|
— | 30 Nov 2023 |
| James C. Sullivan |
3/4/5
Chief Scientific Officer
|
—
class O/S missing
|
—
118,509 shares
|
— | 31 Oct 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
21
Shares
4,440,160
Rows available
21
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q4 2025 Across Filers
Q4 2025 holders
14
Q4 2023 holders
21
Holder diff
7
| Investor | Q4 2025 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q4 2025 value | Q4 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend